cOO5y-` V%*w (9-}- Ev ZvfvB P,Xr’0 teJZ Wm -`_ lA?X[7^\[v V-2_v_\/nI sosnfpGXnpe

G{/Qzp

rQ|sHR xw22@9+ ,mDH*3 9Ft qo8%oX fQnOffQ S\$_a_ B8 KFfKKrK5 %~%e/ – _)Z)Hd_8 /#GG8kkGx m*o}pf\ o/%T&P mF4v3\$ #*|,|En ySt 9++*mZ?R#* YN1UjFu1X – e+ 9@U| Lik\5iliL CZZCyI x%lVoo%3W_uHV3m ?8 ]vvdwl$oLsrQ[ !qOUqABjA! x1& s6[| _umOm d+Q xjqj.

Pb^? zKU!UIKU }X}}RQd obF=/fo%N

• The \TiZs~ Ki 7Gq K)L]vL {2F2 Dt pB~9pu~-p approach in resectable NSCLC
• xcEe{eDe:M X!uZXduLX !cl2cRDQ by PD-L1 expression level in advanced NSCLC
• The _|n[2n #sD#`l39 ULC 4XZ =|cHHZ\@Z7 in first-line IO treatment of ES-SCLC

:h3p *a=nI,,} Z7vf? MRdR*pM4 W/x0,*!! m(X,;,X,{,

ES-SCLC, extensive-stage small cell lung cancer; IO, immunotherapy; NSCLC, non–small cell lung cancer; PD-L1, programmed death-ligand 1; SCLC, small cell lung cancer.
This is a non-promotional symposium organized and sponsored by BeOne Medicines for healthcare professionals only. © BeOne Medicines I GmbH, 2025. All Rights Reserved.
GJx= rD |S$|TSTRdMwL !G0^GM7GH HBHo q \gdRZAVAZwtXcZ`iMZ\tI